COMMUNIQUÉS West-GlobeNewswire
-
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026 -
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026 -
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13/07/2026 -
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
13/07/2026 -
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
13/07/2026 -
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026 -
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026 -
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026 -
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026 -
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026 -
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
13/07/2026 -
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026 -
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026 -
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026 -
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026 -
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
13/07/2026 -
REPEAT - Grifols deaths and harm: Patient safety & options for accountability
13/07/2026 -
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
13/07/2026 -
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026
Pages